Thorat Nanasaheb, Pricl Sabrina, Parchur Abdul K, Somvanshi Sandeep B, Li Qifei, Umrao Sachin, Townley Helen
Nuffield Department of Women's & Reproductive Health, John Radcliffe Hospital, University of Oxford, Oxford, OX3 9DU, UK.
MolBNL@UniTS-DEA, University of Trieste, Piazzale Europa 1, Trieste, 34127, Italy.
Open Res Eur. 2021 Jul 5;1:77. doi: 10.12688/openreseurope.13841.1. eCollection 2021.
Recent clinical cohort studies have highlighted that there is a three-fold greater SARS-Cov-2 infection risk in cancer patients, and overall mortality in individuals with tumours is increased by 41% with respect to general COVID-19 patients. Thus, access to therapeutics and intensive care is compromised for people with both diseases (comorbidity) and there is risk of delayed access to diagnosis. This comorbidity has resulted in extensive burden on the treatment of patients and health care system across the globe; moreover, mortality of hospitalized patients with comorbidity is reported to be 30% higher than for individuals affected by either disease. In this data-driven review, we aim specifically to address drug discoveries and clinical data of cancer management during the COVID-19 pandemic. The review will extensively address the treatment of COVID-19/cancer comorbidity; treatment protocols and new drug discoveries, including the description of drugs currently available in clinical settings; demographic features; and COVID-19 outcomes in cancer patients worldwide.
近期的临床队列研究强调，癌症患者感染新冠病毒的风险要高出三倍，而且肿瘤患者的总体死亡率相较于普通新冠患者增加了41%。因此，患有这两种疾病（合并症）的患者获得治疗和重症监护的机会受到影响，并且存在诊断延迟的风险。这种合并症给全球患者治疗和医疗系统带来了沉重负担；此外，据报道，患有合并症的住院患者死亡率比仅患其中一种疾病的患者高出30%。在这篇基于数据的综述中，我们旨在专门探讨新冠疫情期间癌症管理的药物研发和临床数据。该综述将广泛探讨新冠病毒感染/癌症合并症的治疗；治疗方案和新药研发，包括对目前临床可用药物的描述；人口统计学特征；以及全球癌症患者的新冠病毒感染结果。
